PMGC subsidiary Northstrive files four new patent applications for EL-22 and EL-32 programs

PMGC Holdings Inc.

Filing covers EL-22 in animals (App. 19/191,246) and EL-32 in obesity as monotherapy and with GLP-1 combos.
New patents also include EL-32 animal feed additive (App. 19/191,258) for muscle growth.
Northstrive's IP portfolio now totals 8 applications and 5 issued patents covering USA, Japan, Korea, China.
The filings aim to preserve muscle mass during obesity treatment and expand into animal health market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.